Galecto reports 60% response rate in GALLANT-1 part A; halts Part B to focus on liver disease

Damora Therapeutics, Inc.

Three of five NSCLC patients at 100 mg GB1211 BID plus atezolizumab achieved partial response vs. 22–38% for atezolizumab monotherapy.
Galecto will not initiate Part B of GALLANT-1, reallocating resources to severe liver diseases as part of strategic alternative process.
Two severe dose-limiting skin reactions occurred at 200 mg dose; no such reactions at the recommended 100 mg dose level.
Galecto to supply GB1211 for an investigator-initiated Phase 2 trial at Providence Portland Medical Center expected in early 2024.
Company plans to explore external options for partnering/funding further oncology activities for GB1211.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.